c反应蛋白与白蛋白比（CAR）是食管癌切除术后复发的独立预后因素。

IF 1.7 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-08-01 DOI:10.21873/anticanres.17697

Toru Aoyama, Yukio Maezawa, Itaru Hashimoto, Keisuke Kazama, Mamoru Uchiyama, Kentaro Hara, Hideaki Suematsu, Haruhiko Cho, Ayako Tamagawa, Aya Saito, Norio Yukawa

{"title":"c反应蛋白与白蛋白比（CAR）是食管癌切除术后复发的独立预后因素。","authors":"Toru Aoyama, Yukio Maezawa, Itaru Hashimoto, Keisuke Kazama, Mamoru Uchiyama, Kentaro Hara, Hideaki Suematsu, Haruhiko Cho, Ayako Tamagawa, Aya Saito, Norio Yukawa","doi":"10.21873/anticanres.17697","DOIUrl":null,"url":null,"abstract":"Background/aim: The C-reactive protein to albumin ratio (CAR) is a promising prognostic factor in various malignancies. The aim of the present study was to evaluate the relationship between CAR and unresectable esophageal cancer, and to clarify the role of CAR as a prognostic factor in patients with unresectable esophageal cancer.Patients and methods: We retrospectively reviewed the medical records and collected data from consecutive patients with recurrent EC who received any treatment (including best supportive care) after recurrence at Yokohama City University from 2005 to 2022.Results: One hundred patients were included in this study. According to the previous studies and the 1- and 3-year overall survival (OS) rates, we set the cutoff value of CAR at 0.03. In the present study, 100 patients were divided into CAR-low (n=36) and CAR-high (n=64) groups. The 1- and 3-year OS rates were 84.4% and 58.6%, respectively, in the CAR-low group, and 34.7% and 11.1% in the CAR-high group. There were significant differences between the two groups (p<0.001). In the multivariate analysis, CAR was selected as an independent prognostic factor (hazard ratio=4.771, 95% confidence interval=2.559-8.894, p<0.001). When comparing the treatment clinical course between the CAR-low and CAR-high groups, there was a significant difference in the rate of first-line treatment introduction [CAR-low vs. CAR-high: 94.4% (34/36) vs. 73.4% (47/64); p=0.010].Conclusion: CAR may be a promising prognostic factor in patients with recurrent EC.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 8","pages":"3365-3372"},"PeriodicalIF":1.7000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The C-reactive Protein to Albumin Ratio (CAR) Is an Independent Prognostic Factor for Recurrence in Patients With Esophageal Cancer After Esophagectomy.\",\"authors\":\"Toru Aoyama, Yukio Maezawa, Itaru Hashimoto, Keisuke Kazama, Mamoru Uchiyama, Kentaro Hara, Hideaki Suematsu, Haruhiko Cho, Ayako Tamagawa, Aya Saito, Norio Yukawa\",\"doi\":\"10.21873/anticanres.17697\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background/aim: The C-reactive protein to albumin ratio (CAR) is a promising prognostic factor in various malignancies. The aim of the present study was to evaluate the relationship between CAR and unresectable esophageal cancer, and to clarify the role of CAR as a prognostic factor in patients with unresectable esophageal cancer.Patients and methods: We retrospectively reviewed the medical records and collected data from consecutive patients with recurrent EC who received any treatment (including best supportive care) after recurrence at Yokohama City University from 2005 to 2022.Results: One hundred patients were included in this study. According to the previous studies and the 1- and 3-year overall survival (OS) rates, we set the cutoff value of CAR at 0.03. In the present study, 100 patients were divided into CAR-low (n=36) and CAR-high (n=64) groups. The 1- and 3-year OS rates were 84.4% and 58.6%, respectively, in the CAR-low group, and 34.7% and 11.1% in the CAR-high group. There were significant differences between the two groups (p<0.001). In the multivariate analysis, CAR was selected as an independent prognostic factor (hazard ratio=4.771, 95% confidence interval=2.559-8.894, p<0.001). When comparing the treatment clinical course between the CAR-low and CAR-high groups, there was a significant difference in the rate of first-line treatment introduction [CAR-low vs. CAR-high: 94.4% (34/36) vs. 73.4% (47/64); p=0.010].Conclusion: CAR may be a promising prognostic factor in patients with recurrent EC.\",\"PeriodicalId\":8072,\"journal\":{\"name\":\"Anticancer research\",\"volume\":\"45 8\",\"pages\":\"3365-3372\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anticancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21873/anticanres.17697\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17697","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景/目的：c反应蛋白与白蛋白比值（CAR）是多种恶性肿瘤预后的一个有希望的因素。本研究的目的是评估CAR与不可切除食管癌之间的关系，并阐明CAR作为不可切除食管癌患者预后因素的作用。患者和方法：我们回顾性地回顾了2005年至2022年横滨城市大学复发后接受任何治疗（包括最佳支持治疗）的连续复发性EC患者的医疗记录和收集数据。结果：本研究纳入100例患者。根据以往的研究以及1年和3年的总生存（OS）率，我们将CAR的临界值定为0.03。本研究将100例患者分为CAR-low组（n=36）和CAR-high组（n=64）。CAR-low组1年和3年的OS率分别为84.4%和58.6%，CAR-high组为34.7%和11.1%。两组间有显著性差异(ppvs。CAR-high: 94.4% (34/36) vs. 73.4% (47/64)；p = 0.010)。结论：CAR可能是复发性EC患者预后的重要因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The C-reactive Protein to Albumin Ratio (CAR) Is an Independent Prognostic Factor for Recurrence in Patients With Esophageal Cancer After Esophagectomy.

Background/aim: The C-reactive protein to albumin ratio (CAR) is a promising prognostic factor in various malignancies. The aim of the present study was to evaluate the relationship between CAR and unresectable esophageal cancer, and to clarify the role of CAR as a prognostic factor in patients with unresectable esophageal cancer.

Patients and methods: We retrospectively reviewed the medical records and collected data from consecutive patients with recurrent EC who received any treatment (including best supportive care) after recurrence at Yokohama City University from 2005 to 2022.

Results: One hundred patients were included in this study. According to the previous studies and the 1- and 3-year overall survival (OS) rates, we set the cutoff value of CAR at 0.03. In the present study, 100 patients were divided into CAR-low (n=36) and CAR-high (n=64) groups. The 1- and 3-year OS rates were 84.4% and 58.6%, respectively, in the CAR-low group, and 34.7% and 11.1% in the CAR-high group. There were significant differences between the two groups (p<0.001). In the multivariate analysis, CAR was selected as an independent prognostic factor (hazard ratio=4.771, 95% confidence interval=2.559-8.894, p<0.001). When comparing the treatment clinical course between the CAR-low and CAR-high groups, there was a significant difference in the rate of first-line treatment introduction [CAR-low vs. CAR-high: 94.4% (34/36) vs. 73.4% (47/64); p=0.010].

Conclusion: CAR may be a promising prognostic factor in patients with recurrent EC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.